January 22, 2024
admin
Lupin get US FDA nod for Gout Medicine
Lupin’s shares reached a new pinnacle, surging to a 52-week high of INR 1,439.95 on NSE early on 19 January 2024. The boost came after the United States Food and Drug Administration (US FDA) granted approval for the launch of Lupin’s Febuxostat tablets, a drug aimed at treating chronic hyperuricemia in adult patients with gout. This approval is part of Lupin’s ongoing series of successes in gaining FDA authorization for its products in the American market.
Febuxostat tablets are designed for individuals with gout who haven’t responded adequately to allopurinol or are intolerant to it. Lupin highlighted that this latest drug will be manufactured at its Pithampur facility.
This approval closely follows Lupin’s recent green light from the FDA to sell Propranolol Hydrochloride Extended-Release Capsules USP, and the launch of Bromfenac Ophthalmic Solution, 0.07%. Additionally, Lupin has received FDA clearance for dapagliflozin and saxagliptin tablets, intended to improve glycemic control in adults with type 2 diabetes. The positive developments continue to reinforce Lupin’s position in the competitive pharmaceutical market.
Quicklinks
